Bound Structure and Biochemical Mechanism of Action of BI 201335, a Potent, Non-covalent Inhibitor of HCV NS3-NS4A Protease

被引：2
|
作者：
Lemke, Christopher T. [1 ]
Zhao, Songping [1 ]
Goudreau, Nathalie [1 ]
Hucke, Oliver [1 ]
Thibeault, Diane [1 ]
Llinas-Brunet, Montse [1 ]
White, Peter W. [1 ]
机构：
[1] Boehringer Ingelheim Canada Ltd, Laval, PQ, Canada
来源：
ANTIVIRAL RESEARCH | 2010年 / 86卷 / 01期
关键词：
D O I：
10.1016/j.antiviral.2010.02.336
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
16
引用
收藏
页码：A20 / A21
页数：2
相关论文
共 50 条
  • [21] IN VITRO SELECTION OF RESISTANCE TO GS-9451, A NOVEL AND POTENT INHIBITOR OF HCV NS3 PROTEASE
    Yang, Huiling
    Appleby, Todd C.
    Chen, Xiaowu
    Delaney, William E.
    HEPATOLOGY, 2011, 54 : 1352A - 1352A
  • [22] Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors
    Shunmugam, Letitia
    Ramharack, Pritika
    Soliman, Mahmoud E. S.
    PROTEIN JOURNAL, 2017, 36 (05): : 397 - 406
  • [23] Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors
    Letitia Shunmugam
    Pritika Ramharack
    Mahmoud E. S. Soliman
    The Protein Journal, 2017, 36 : 397 - 406
  • [24] Binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target
    Cummings, Maxwell D.
    Lindberg, Jimmy
    Lin, Tse-I
    de Kock, Herman
    Lenz, Oliver
    Lilja, Elisabet
    Fellander, Sara
    Baraznenok, Vera
    Nystrom, Susanne
    Nilsson, Magnus
    Vrang, Lotta
    Edlund, Michael
    Rosenquist, Asa
    Samuelsson, Bertil
    Raboisson, Pierre
    Simmen, Kenneth
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [25] GRAZOPREVIR POTASSIUM HCV NS3 NS4A protease inhibitor Anti-hepatitis C virus drug
    Majumdar, A.
    Gilliam, B. L.
    DRUGS OF THE FUTURE, 2016, 41 (02) : 85 - 109
  • [26] Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease
    Rudd, Michael T.
    McCauley, John A.
    Romano, Joseph J.
    Butcher, John W.
    Bush, Kimberly
    McIntyre, Charles J.
    Nguyen, Kevin T.
    Gilbert, Kevin F.
    Lyle, Terry A.
    Holloway, M. Katharine
    Wan, Bang-Lin
    Vacca, Joseph P.
    Summa, Vincenzo
    Harper, Steven
    Rowley, Michael
    Carroll, Steven S.
    Burlein, Christine
    DiMuzio, Jillian M.
    Gates, Adam
    Graham, Donald J.
    Huang, Qian
    Ludmerer, Steven W.
    McClain, Stephanie
    McHale, Carolyn
    Stahlhut, Mark
    Fandozzi, Christine
    Taylor, Anne
    Trainor, Nicole
    Olsen, David B.
    Liverton, Nigel J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (23) : 7201 - 7206
  • [27] HIGHLY POTENT HCV NS5B INHIBITOR WITH ORIGINAL MECHANISM OF ACTION IDENTIFIED WITH THE 3D-SCREEN TECHNOLOGY
    Lahmar, M.
    Berecibar, A.
    Valarche, I.
    Martin, A.
    Piessens, A.
    Batard, L.
    Freslon-Evain, C.
    Fernagut, C.
    Guedat, P.
    Mehtali, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S480 - S480
  • [28] TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection
    Tsantrizos, Youla S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 871 - 881
  • [29] Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships
    Hu, Katherine
    Zhu, Zhaowen
    Mathahs, Meleah M.
    Tran, Huy
    Bommer, Jerry
    Testa, Charles A.
    Schmidt, Warren N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 757 - 771
  • [30] PHARMACOKINETIC INTERACTION OF HCV NS3/4A PROTEASE INHIBITOR VANIPREVIR AND ROSUVASTATIN.
    Orito, Y.
    Iwasa, T.
    Uemura, N.
    Fujimoto, G.
    Yama, S.
    Gao, W.
    Caro, L.
    Fandozzi, C.
    Prucksaritanont, T.
    Anderson, M.
    Butterton, J.
    Hasegawa, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S24 - S25
12345